@mchilberg $PFE $SGMO Pfizer &amp; Sangamo updated Phase 1/2 results of SB-525 #GeneTherapy for #hemophilia A:

- 5/5 pts showed sustained FVIII activity levels, with a median of 64.2% up to 61 weeks at 3E13 vg/kg dose
- No bleeding events or required FVIII infusions

https://t.co/qumDpDX3x3